LABP RSI Chart
Last 7 days
0.6%
Last 30 days
3.7%
Last 90 days
301.3%
Trailing 12 Months
7648.3%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2022 | 0 | 0 | 0 | 0 |
2021 | 0 | 72.0M | 36.0M | 18.0M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Feb 28, 2023 | bassaganya-riera josep | sold | - | - | -786,299 | - |
Feb 28, 2023 | bassaganya-riera josep | sold | - | - | -3,470,740 | - |
Feb 28, 2023 | bassaganya-riera josep | sold | - | - | -1,463,830 | - |
Sep 23, 2022 | rtw investments, lp | sold | -207,000 | 0.69 | -300,000 | - |
Aug 05, 2022 | bassaganya-riera josep | gifted | - | - | 500,000 | - |
Aug 05, 2022 | bassaganya-riera josep | gifted | - | - | -500,000 | - |
Mar 23, 2022 | bassaganya-riera josep | gifted | - | - | -650,000 | - |
Dec 28, 2021 | bassaganya-riera josep | gifted | - | - | -1,000,000 | - |
Dec 20, 2021 | bassaganya-riera josep | sold | -157,804 | 4.754 | -33,194 | - |
Dec 17, 2021 | bassaganya-riera josep | sold | -174,096 | 4.836 | -36,000 | - |
Which funds bought or sold LABP recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | MORGAN STANLEY | new | - | 279 | 279 | -% |
May 15, 2024 | PenderFund Capital Management Ltd. | new | - | 270,842 | 270,842 | 0.07% |
May 15, 2024 | Black Maple Capital Management LP | new | - | 223,499 | 223,499 | 0.14% |
May 15, 2024 | Tower Research Capital LLC (TRC) | new | - | 19,246 | 19,246 | -% |
May 15, 2024 | PERCEPTIVE ADVISORS LLC | unchanged | - | 26,498,200 | 31,940,600 | 0.56% |
May 15, 2024 | Royal Bank of Canada | new | - | 1,000 | 1,000 | -% |
May 14, 2024 | MACQUARIE GROUP LTD | unchanged | - | 262,000 | 316,000 | -% |
May 13, 2024 | GEODE CAPITAL MANAGEMENT, LLC | unchanged | - | 224,856 | 270,986 | -% |
May 13, 2024 | UBS Group AG | added | 9,623 | 87,570 | 87,724 | -% |
May 13, 2024 | RENAISSANCE TECHNOLOGIES LLC | added | 67.76 | 365,000 | 406,000 | -% |
Unveiling Landos Biopharma, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Landos Biopharma, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Landos Biopharma, Inc. News
Income Statement (Quarterly) | |||||
Description | (%) Q/Q | 2022Q4 | 2021Q4 | 2021Q3 | 2021Q2 |
Revenue | - | - | - | - | 18,000,000 |
Operating Expenses | -68.1% | 6,513,000 | 20,395,500 | 12,403,000 | 14,118,000 |
S&GA Expenses | -55.4% | 3,099,000 | 6,951,500 | 3,059,000 | 2,596,000 |
R&D Expenses | -74.6% | 3,414,000 | 13,444,000 | 9,344,000 | 11,522,000 |
EBITDA Margin | 1.1% | -2.08 | -2.10 | -0.81 | -0.34 |
Interest Expenses | - | 1,281,000 | - | - | - |
Earnings Before Taxes | 74.0% | -5,232,000 | -20,097,000 | -12,604,000 | 4,097,000 |
EBT Margin | -2.2% | -2.18 | -2.13 | -0.82 | -0.35 |
Net Income | 74.0% | -5,232,000 | -20,097,000 | -12,604,000 | 4,097,000 |
Net Income Margin | -2.2% | -2.18 | -2.13 | -0.82 | -0.35 |
Free Cashflow | 69.2% | -3,699,000 | -12,020,000 | -12,108,000 | 9,251,000 |
Balance Sheet | |||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 |
Assets | -21.4% | 29,896 | 38,040 | 43,230 | 46,285 | 51,184 | 45,253 | 49,488 | 58,038 | 77,610 | 92,879 | 105,098 | 118,291 | 110,210 | 30,332 |
Current Assets | -21.4% | 29,896 | 38,040 | 43,230 | 46,285 | 51,184 | 45,253 | 49,488 | 58,038 | 77,359 | 92,146 | 104,318 | 117,727 | 109,745 | 29,888 |
Cash Equivalents | -22.5% | 29,054 | 37,499 | 42,408 | 44,049 | 45,244 | 36,640 | 28,880 | 19,241 | 11,288 | 8,305 | 17,893 | 18,687 | 8,572 | 2,416 |
Net PPE | - | - | - | - | - | - | - | - | - | 224 | 707 | 780 | 564 | 465 | 444 |
Liabilities | 7.9% | 6,742 | 6,249 | 5,566 | 3,015 | 4,160 | 6,122 | 5,475 | 6,510 | 15,507 | 16,611 | 11,180 | 12,679 | 9,031 | 11,310 |
Current Liabilities | 7.9% | 6,742 | 6,249 | 5,566 | 3,015 | 4,160 | 6,122 | 5,475 | 6,510 | 15,507 | 16,611 | 11,095 | 12,530 | 8,819 | 11,034 |
Shareholder's Equity | -27.2% | 23,154 | 31,791 | 37,664 | 43,270 | 47,024 | 39,131 | 44,013 | 51,528 | 62,103 | 76,268 | 93,918 | 105,612 | 101,179 | - |
Retained Earnings | -5.7% | -164,300 | -155,400 | -149,200 | -143,383 | -139,461 | -133,427 | -128,200 | -120,299 | -109,000 | -94,151 | -74,054 | -61,450 | -65,547 | -55,729 |
Additional Paid-In Capital | 0.1% | 187,382 | 187,122 | 186,877 | 186,629 | 186,094 | 172,575 | 172,016 | 171,816 | 171,182 | 170,241 | 167,440 | 166,805 | 166,429 | 1,633 |
Shares Outstanding | 0.1% | 3,119 | 3,117 | 3,117 | 3,117 | 3,117 | 4,025 | 4,025 | 4,025 | 4,025 | 4,025 | 3,666 | 2,988 | - | - |
Float | - | - | - | - | 5,600 | - | - | - | 8,500 | - | - | - | 89,900 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 |
Cashflow From Operations | -71.0% | -8,498 | -4,969 | -2,228 | -5,110 | -8,170 | -3,699 | -7,573 | -17,997 | -16,502 | -12,057 | -11,844 | 9,400 | -12,560 | -8,391 | -5,379 | -5,824 | -3,368 |
Share Based Compensation | 6.1% | 260 | 245 | 248 | 254 | 224 | 196 | 200 | 634 | 941 | 2,428 | 355 | 312 | 1,023 | 833 | - | - | - |
Cashflow From Investing | -100.0% | - | 63.00 | 634 | 3,974 | 3,104 | 11,471 | 17,212 | 25,871 | 19,506 | 1,796 | 10,831 | 715 | -72,048 | 6,930 | 3,464 | 2,030 | 1,707 |
Cashflow From Financing | - | - | - | - | -99.00 | 13,666 | - | - | - | - | 624 | 219 | - | 90,764 | - | - | - | - |
Buy Backs | - | - | - | - | - | 3,000 | - | - | - | - | - | - | - | - | - | - | - | - |
Condensed Consolidated Statements of Operations and Comprehensive Loss Income (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expenses: | ||
Research and development | $ 3,151 | $ 3,326 |
General and administrative | 6,144 | 3,153 |
Total operating expenses | 9,295 | 6,479 |
Loss from operations | (9,295) | (6,479) |
Other income: | ||
Loss from foreign exchange | (3) | (4) |
Interest and other income, net | 401 | 449 |
Other income, net | 398 | 445 |
Net loss | $ (8,897) | $ (6,034) |
Net loss per common stock, basic | $ (1.43) | $ (0.93) |
Net loss per common stock, diluted | $ (1.43) | $ (0.93) |
Weighted-average shares used to compute net loss income per share, basic | 6,207,637 | 6,484,233 |
Weighted-average shares used to compute net loss income per share, diluted | 6,207,637 | 6,484,233 |
Net loss | $ (8,897) | $ (6,034) |
Unrealized gain on available-for-sale marketable securities | 0 | 136 |
Comprehensive loss | $ (8,897) | $ (5,898) |
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 29,004 | $ 37,499 |
Restricted Cash | 50 | 50 |
Prepaid expenses and other current assets | 842 | 491 |
Total current assets | 29,896 | 38,040 |
Total assets | 29,896 | 38,040 |
Current liabilities: | ||
Accounts payable | 1,565 | 1,375 |
Accrued liabilities | 5,177 | 4,874 |
Total current liabilities | 6,742 | 6,249 |
Total liabilities | 6,742 | 6,249 |
Commitments and contingencies (Note 7) | ||
Stockholders' equity: | ||
Preferred stock, $0.01 par value; 10,000,000 shares authorized, no shares issued and outstanding as of March 31, 2024 and December 31, 2023 | 0 | 0 |
Common stock, $0.01 par value; 20,000,000 shares authorized, 3,116,729 shares issued and outstanding as of March 31, 2024 and December 31, 2023 | 31 | 31 |
Additional paid-in capital | 187,382 | 187,122 |
Accumulated deficit | (164,259) | (155,362) |
Total stockholders' equity | 23,154 | 31,791 |
Total liabilities and stockholders' equity | $ 29,896 | $ 38,040 |